Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies

Tirabrutinib is a Bruton’s tyrosine kinase inhibitor for treating B-cell malignancies. We report the final results of a Phase I study of tirabrutinib in 17 Japanese patients with B-cell malignancies. Patients were administered tirabrutinib at a dose of 160 mg, 320 mg, or 480 mg once daily, or 300 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Munakata, Wataru, Ando, Kiyoshi, Yokoyama, Masahiro, Fukuhara, Noriko, Yamamoto, Kazuhito, Fukuhara, Suguru, Ohmachi, Ken, Mishima, Yuko, Ichikawa, Satoshi, Ogiya, Daisuke, Aoi, Arata, Hatsumichi, Masahiro, Tobinai, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063512/
https://www.ncbi.nlm.nih.gov/pubmed/36576659
http://dx.doi.org/10.1007/s12185-022-03514-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063512/
https://www.ncbi.nlm.nih.gov/pubmed/36576659
http://dx.doi.org/10.1007/s12185-022-03514-6

Ejemplares similares